The first transplant using cord blood-derived hematopoietic stem cells was performed in October 1988. Since that year, remarkable achievements have been made in terms of research into umbilical cord blood-derived hematopoietic and progenitor cells. More than 40,000 UCB transplants (UCBTs) have been performed across different geographies of the world, in both children and adults, to treat diseases that include hematologic, metabolic, immunologic, neoplastic, and neurologic disorders. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
Pivotal Trends Impacting the Global Cord Blood and Tissue Industry in 2023
The cord blood industry came into existence in the early 1990’s with the formation of several cord blood banks in the U.S. and worldwide. It has been 40 years since it was first proposed that stem and progenitor cells were present in human cord blood. [Read more…]
First Patient Dosed with Gamida Cell’s Expanded Cord Blood Cell Therapy, Omisirge™
Omisirge is the world’s 1st U.S. FDA approved product that is a expanded umbilical cord blood cell therapy.
It is also the only allogeneic stem cell therapy approved by the U.S. FDA on the basis of a global randomized Phase 3 trial.
Rapid onboarding of transplant centers and significant payer coverage demonstrate strong launch progress.
Boston, MA, September 27, 2023 –– Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, announced that the first patient has received a stem cell transplant with Omisirge (omidubicel-onlv). [Read more…]
What are Placental Stem Cells and What are They Used For?
What are placental stem cells and what are placental stem cells used for? As placental stem cells get explored for a variety of therapeutic applications, these questions become increasingly important. The opportunity to collect placental stem cells is also a once in a lifetime opportunity. [Read more…]
Utilization of Umbilical Cord Blood in HSCT versus Regenerative Medicine
(Percentage Breakdown)
Since its first successful use more than three decades ago, umbilical cord blood has become an increasingly important source of stem cells for transplants for bone marrow failures, leukemia, lymphoma, sickle cell anemia, and other life-threatening diseases. Over 40,000 cord blood transplants have been performed worldwide for a wide variety of malignant and non-malignant disorders. The first successful cord blood stem cell transplant was performed in 1988 as a treatment for a 5-year-old boy with Fanconi Anemia; his newborn sister’s umbilical cord blood saved his life. Today, more than 80 diseases have FDA-approved cord blood stem cell transplant treatments. [Read more…]
- 1
- 2
- 3
- …
- 61
- Next Page »